中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2009年
33期
1-4
,共4页
李勇%崔苏扬%靳艳卿%李榕%周路阳%顾小萍
李勇%崔囌颺%靳豔卿%李榕%週路暘%顧小萍
리용%최소양%근염경%리용%주로양%고소평
抑肽酶%肝移植%血液保护
抑肽酶%肝移植%血液保護
억태매%간이식%혈액보호
Aprotinin%Liver transplantation%Blood conservation
目的 研究抑肽酶对肝移植患者围手术期期血液保护的效应.方法 将40例行原位背驮式肝移植术患者随机分为两组:对照组(C组)20例,抑肽酶组(A组)20例.A组首量1 ×106kU,持续量0.25×106kU/h持续静脉泵注抑肽酶,直至术毕,C组泵注等量0.9%氯化钠溶液.于术前(T1)、无肝期前5min(T2)、新肝期5 min(T3)、新肝期30 min(T4)和新肝期120 min(T5)采集颈内静脉血检测凝血功能,包括凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)、纤维蛋白原(TIB)、血栓弹力扫描仪(TEG)的反应时间(R)等.记录两组术中总出血量和血浆、血小板、液体输入量,并记录两组回收血洗涤量和红细胞悬液洗涤量.结果 A组患者术中总出血量、回收血洗涤量、红细胞悬液洗涤量及血浆、白蛋白、胶体输入量[(3708±1910)、(1321±488)、(2121±785)、(2568±904)、(200±63)、(3830±897)ml]明显低于C组[(5676±2241)、(2034±734)、(2697±978)、(3725±1374)、(259±83)、(5065±1505)ml](P<0.01或<0.05).两组T1各凝血功能指标比较,差异均无统计学意义;T2~T5A组的PT、APRR、TT和R均较C组同一时间点缩短(P<0.05或P<0.01).结论 在肝移植术中应用抑肽酶能够有效地改善围手术期期凝血功能,减少术中出血量,减少异体血及血浆代用品的输注量,具有很好的血液保护效应.
目的 研究抑肽酶對肝移植患者圍手術期期血液保護的效應.方法 將40例行原位揹馱式肝移植術患者隨機分為兩組:對照組(C組)20例,抑肽酶組(A組)20例.A組首量1 ×106kU,持續量0.25×106kU/h持續靜脈泵註抑肽酶,直至術畢,C組泵註等量0.9%氯化鈉溶液.于術前(T1)、無肝期前5min(T2)、新肝期5 min(T3)、新肝期30 min(T4)和新肝期120 min(T5)採集頸內靜脈血檢測凝血功能,包括凝血酶原時間(PT)、活化部分凝血活酶時間(APTT)、凝血酶時間(TT)、纖維蛋白原(TIB)、血栓彈力掃描儀(TEG)的反應時間(R)等.記錄兩組術中總齣血量和血漿、血小闆、液體輸入量,併記錄兩組迴收血洗滌量和紅細胞懸液洗滌量.結果 A組患者術中總齣血量、迴收血洗滌量、紅細胞懸液洗滌量及血漿、白蛋白、膠體輸入量[(3708±1910)、(1321±488)、(2121±785)、(2568±904)、(200±63)、(3830±897)ml]明顯低于C組[(5676±2241)、(2034±734)、(2697±978)、(3725±1374)、(259±83)、(5065±1505)ml](P<0.01或<0.05).兩組T1各凝血功能指標比較,差異均無統計學意義;T2~T5A組的PT、APRR、TT和R均較C組同一時間點縮短(P<0.05或P<0.01).結論 在肝移植術中應用抑肽酶能夠有效地改善圍手術期期凝血功能,減少術中齣血量,減少異體血及血漿代用品的輸註量,具有很好的血液保護效應.
목적 연구억태매대간이식환자위수술기기혈액보호적효응.방법 장40례행원위배타식간이식술환자수궤분위량조:대조조(C조)20례,억태매조(A조)20례.A조수량1 ×106kU,지속량0.25×106kU/h지속정맥빙주억태매,직지술필,C조빙주등량0.9%록화납용액.우술전(T1)、무간기전5min(T2)、신간기5 min(T3)、신간기30 min(T4)화신간기120 min(T5)채집경내정맥혈검측응혈공능,포괄응혈매원시간(PT)、활화부분응혈활매시간(APTT)、응혈매시간(TT)、섬유단백원(TIB)、혈전탄력소묘의(TEG)적반응시간(R)등.기록량조술중총출혈량화혈장、혈소판、액체수입량,병기록량조회수혈세조량화홍세포현액세조량.결과 A조환자술중총출혈량、회수혈세조량、홍세포현액세조량급혈장、백단백、효체수입량[(3708±1910)、(1321±488)、(2121±785)、(2568±904)、(200±63)、(3830±897)ml]명현저우C조[(5676±2241)、(2034±734)、(2697±978)、(3725±1374)、(259±83)、(5065±1505)ml](P<0.01혹<0.05).량조T1각응혈공능지표비교,차이균무통계학의의;T2~T5A조적PT、APRR、TT화R균교C조동일시간점축단(P<0.05혹P<0.01).결론 재간이식술중응용억태매능구유효지개선위수술기기응혈공능,감소술중출혈량,감소이체혈급혈장대용품적수주량,구유흔호적혈액보호효응.
Objective To investigate the effect of aprotinin on perioperative blood conservation in patients undergoing orthotopic liver transplantation (OLT). Methods Forty patients with end-stage liver diseases, undergoing OLT were randomly divided into two groups: aprotinin group received intravenous infusion aprotinin continuously during the whole operation (group A, 20 cases)and control group received the same amount of normal saline instead of aprotinin (group C, 20 cases). Internal jugular vein blood sampleswere collected to measure the coagulation variables including prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (FIB), and R value of thrombelastography (TEG) on time points:before skin incision (T1), 5 min in anhepafic phase (T2), 5 min, 30 min and 120 min after reperfusion phase (T3, T4, T5). The volume of total blood loss, red blood cell, blood plasma, platelet and liquid transfusion during operation were observed. Results The volume of total blood loss during operation, blood loss recovery(washed by cell saver)during operation, red blood cell (washed by cell saver) and blood plasma, albumin, colloid liquid transfusion perioperation was (3708 ± 1910),(1321 + 488),(2121 ± 785), (2568 ± 904), (200 ± 63), (3830 ± 897) ml respectively in group A. The matched pair analysis volume was (5676 ± 2241), (2034 ± 734), (2697 ± 978), (3725 ± 1374), (259 ± 83), (5065 ± 1505) ml respectively in group C. Compared with group C, these volume in group A were lower (P < 0.01 or < 0.05). There was no significant difference in each item of coagulation function at T1 time point between the two groups. Each item of coagulation function (PT, APTT, TT and R value of TEG) at T2-T5 time point in group A was better than that in group C (P < 0.05 or < 0.01). Conclusion Aprotinin used in end-stage hver diseases patients during OLT can ameliorate coagulation function, decrease the blood loss perioperation, reduce the amount of homologous blood and blood plasma substitute transfusion, it has a good effect on perioperative blood conservation.